KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Debt (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Non-Current Debt data on record, last reported at $2.6 billion in Q4 2025.

  • For Q4 2025, Non-Current Debt rose 18.66% year-over-year to $2.6 billion; the TTM value through Dec 2025 reached $2.6 billion, up 18.66%, while the annual FY2025 figure was $2.6 billion, 18.66% up from the prior year.
  • Non-Current Debt reached $2.6 billion in Q4 2025 per AMRX's latest filing, roughly flat from $2.6 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $2.7 billion in Q1 2021 and bottomed at $37.2 million in Q2 2021.
  • Average Non-Current Debt over 5 years is $2.0 billion, with a median of $2.4 billion recorded in 2023.
  • Peak YoY movement for Non-Current Debt: surged 7632.81% in 2021, then plummeted 98.59% in 2022.
  • A 5-year view of Non-Current Debt shows it stood at $2.7 billion in 2021, then dropped by 3.29% to $2.6 billion in 2022, then dropped by 7.95% to $2.4 billion in 2023, then decreased by 9.4% to $2.2 billion in 2024, then increased by 18.66% to $2.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $2.6 billion in Q4 2025, $2.6 billion in Q3 2025, and $2.1 billion in Q2 2025.